St. Jude Scientists Develop Novel Bispecific CAR-T Design to Combat Acute Myeloid Leukemia Relapse
核心洞察
St. Jude Children's Research Hospital scientists have developed a novel bispecific CAR-T cell design that targets two different cancer-related proteins simultaneously to overcome immune escape in acute myeloid leukemia.
The innovative approach uses a small peptide as a second binding domain connected by a flexible linker, outperforming traditional single-targeted CARs in both laboratory and animal studies.
Researchers employed AI-based structural prediction tools, including AlphaFold, to optimize the CAR design and demonstrate that shorter, more flexible linkers enhance therapeutic efficacy.
St. Jude Children's Research Hospital scientists have developed an innovative bispecific chimeric antigen receptor (CAR) T-cell design that significantly improves immunotherapy outcomes for acute myeloid leukemia (AML), addressing a critical challenge in cancer treatment where high relapse rates lead to poor patient prognosis.
The breakthrough research, published in Cell Reports Medicine, tackles the persistent problem of immune escape in CAR-T therapy, where cancer cells lacking the targeted protein continue to grow and cause treatment failure. The St. Jude team's solution involves targeting two different cancer-related proteins simultaneously rather than the conventional single-target approach.
Novel Dual-Targeting Architecture
The researchers created a unique single-molecule CAR that incorporates both an antibody binding region for one target and a small peptide that binds a separate target. "The two different binding domains of the CAR are like having two barcode scanners instead of one, looking for their appropriate barcode, the targeted cancer-related proteins," explained senior corresponding author Dr. Paulina Velasquez from St. Jude's Department of Bone Marrow Transplantation and Cellular Therapy.
This design represents a significant departure from previous bispecific CAR approaches. "Prior bispecific CAR approaches use two antibody-based single-chain variable fragments, which are physically large molecules and can get in each other's way, sometimes leading to poor or inefficient binding," said first author Dr. Jaquelyn Zoine. "Our approach instead added a small peptide, enabling our CAR to engage either platform to prevent immune escape."
The dual-targeted CARs demonstrated superior performance compared to single-targeted CARs in both in vitro and in vivo experiments, showing promise for improving CAR T-cell function against AML.
AI-Powered Structural Optimization
A key innovation in the research involved using artificial intelligence-based structure prediction tools, including AlphaFold, to optimize the CAR design. The team focused on understanding how the physical structure of the targeting molecule and its connecting linker affects therapeutic efficacy.
"We are one of few groups in the world to use AI-based structure prediction tools for CAR design," noted second author Dr. Kalyan Immadisetty. The computational analysis revealed that shorter, more flexible linkers work better than rigid alternatives.
Co-author Dr. M. Madan Babu, director of St. Jude's Center of Excellence for Data-Driven Discovery, explained the structural rationale: "If we have a rigid linker connecting the barcode scanners, it can only scan a restricted volume on the cancer cell, making it less effective in finding the targets. We found when you have a linker of sufficient flexibility and shorter length so it doesn't fold onto itself, it can scan a much larger volume and is more likely to find the target proteins on the cancer cell."
Broader Therapeutic Implications
The research has implications extending beyond AML treatment. "One of the most exciting aspects of the study is that this approach can be widely extrapolated to other tumours," Dr. Velasquez emphasized. "We focused on leukaemia, but combining bispecific CAR design with computational predictions can be widely extrapolated for other tumours such as solid and brain tumours."
The computational approach developed by the team provides a framework that other researchers can adopt for their own CAR designs. "Most importantly, others can now use our computational approach for designing their CARs," Dr. Immadisetty concluded. "And hopefully, it will help them understand the efficacy of their CAR technology and lead to overall improvements for leukaemia and other malignancies."
Addressing Clinical Need
The research addresses a critical unmet medical need in AML treatment, where the relapse rate following CAR-T therapy remains high, contributing to the disease's overall poor prognosis. By creating a mechanism that can target cancer cells through two different pathways, the bispecific design offers a potential solution to the immune escape problem that has limited the effectiveness of current CAR-T approaches.
The study represents a significant step forward in personalized cancer immunotherapy, combining innovative molecular design with cutting-edge computational tools to create more effective treatments for patients with challenging blood cancers.